Introduction Omalizumab, the first biological treatment for severe allergic bronchial asthma,
has been on the market for more than a decade. Omalizumab was initially considered to be …

Despite the expansion of the understanding in asthma pathophysiology and the continual
advances in disease management, a small subgroup of patients remain partially controlled …

Asthma is a heterogeneous syndrome with numerous underlining molecular and
inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple …

Objectives: Omalizumab is a recombinant humanized IgG1 monoclonal anti-IgE antibody,
used for the treatment of severe refractory allergic asthma. However, not all patients with IgE …

Background Patients with severe allergic and eosinophilic asthma could qualify for different
biologic therapies. Objective To evaluate the efficacy and safety of weight-based …

Asthma is a common condition that causes episodic expiratory airflow limitation due to
bronchial smooth muscle constriction and airways inflammation resulting in increased …

Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now
well recognized that asthma is a chronic inflammatory disease of the airways. The …

The implications of boosting Omalizumab treatment (OT) in patients with severe allergic
asthma (SAA) remain unclear. The study aimed to explore and compare the 12-month …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …

Abstract Background Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody,
has demonstrated efficacy in clinical trials conducted in patients with moderate to severe …